What Does Shark Tank’s Mark Cuban Know About Fixing Health Care? Are There Lessons for All of Us?

Mark Cuban

M arianne O’Hare : Welcome to Conversations on Health Care . This week , we welcome
renowned entrepreneur and popular Shark Tank h ost, Mark Cuban,
who is seeking to disrupt the prescription drug market, offering low
cost medications direct to consum ers online w ith his new venture
Cost Plus Drugs.

Mark Cuban: The challenge for patients as it applies to health care, we’re not as
transparent as we need to be, and when you're not transparent, then
people don’t trust you.

Marianne O’Hare: We hear from F act C he ck.org ’ s Man aging Editor Lori Robertson , and
we end with a bright idea. Now, here are your hosts , Mark Ma s selli
and Margaret Flinter.

[Music]

Mark Masselli: Our guest today is a well - known entrepreneur , responsible for
multiple startups in digital media, s oftware deve lopment on
blockchain. The billionaire businessman is a popular co - host on the hit
series Shark Tank, and i s the principal owner of the Dallas Mavericks
Basketball t eam .

Margaret Flinter: He has increasingly lent his support on Shark Tank to sta rtups th at
s eek to address inequities in American health care . And recently, he
launched his own enterprise, the Mark Cuban Cost Plus Drug
Company , a public benefit company, an online direct to consumer
pharmacy that aims to take on the high cost of presc ription drug s.

Mark Masselli: Well Mark Cuban, welcome to Conversations on Health Care .

Mark Cuban: Thanks for hav ing me. I'm excited to be here.

Mark Masselli: Mark , prescription drugs now are a major factor in the almost $4
trillion a year that gets spe nt in he alth care in this country . One out of
five Americans can't afford at least one of their prescription
medication . And you say there are far too many middlemen in the
prescription drug pipeline, which significantly adds to the cost , and
you're promi sing to r adi cally be transparent about the cost. How does
that differ from the status quo ?

Mark Cuban: Significantly . I mean, there's very much a vertically integrated
environment right now where insurance companies own PBMs and
own retail pharmacies and are e xpand ing int o other areas of health
care . And they keep on creating these fortresses where they control
the left pocket and the right pocket , and by having so much control,
they're able to create an environment where pricing is opaque , i t's
confusing . And be cau se they'r e able to contract with insurers and
major corporations, they're able to play these games where they say,
“ Okay, if you want access to all these lives, then you have to do
business the way we want to do business . ” And that is unfortunate ,

Mark Cuban

and cre a tes a lot o f p ricing distortion for patients.

Margaret Flinter: Well Mark, our organization delivers care to a large vulnerable
population , and I think we do a pretty good job of helping patients
access prescriptions at prices they can afford. But it d oes take an
enormous effort. Medicare itself had been blocked from negotiating
drug prices. But that's now changed under the President's Inflation
Reduction Act. How do you think this new development is going to
shift these issues that you' ve described in the marketpl ace?

Mark Cuban: I think it'll improve things obviously for the 10 drugs and then moving
up to more drugs over a period of time. I think it's great for people on
insulin who are on Medicare, doesn't do much of anything for
everybody else . So where th ere are out of pocket limits, the $2,000
will make a big difference as well. But , until you get to that $2,000
limit, there is going to be challenges for Medicare patients. And on
top of that, you add Medicare Advantage, which is completely
dis torted, co mp letely confusing, rewarding not to the patients, but to
the owner of the Medicare Advantage company. There's still a lot of
messiness , and that's one of the things we're hoping to attack.

Mark Masselli: Mark, you've just inked your first health plan deal , Capital Blue Cross
in Pennsylvania . This space is highly competitive , so how will it work
for the consumers?

Mark Cuban: Well, the way it starts is they'll refer their patients to us , and then
using a form they'll reimburse them. We're updating o ur softw are so
that shortly it'll all be automated. So you'll just buy through Cost Plus
Drugs , and everything from there in terms of applying to your
deductibles, all those things will be handled on an automated basis.
And we're also partnering with Prime Therape utic s, which allows us to
talk to a lot of other Blues , and we're hoping that leads to many other
insurers to work with us. And obviously, we're also talking to many,
many, many independents , because you know, other than the big
three, it's very dif ficult to co ntrol their own pricing . And they're
paying premiums, and they're kind of caught in the vortex of dealing
with the PBMs. And so we're trying to yank them out of there, and the
response has been great.

Margaret Flinter: Well, Mark , it certainly seem s t hat this approach could save billions of
dollars for consumers , but still only targets about 20% of the
medication market , the generics . And non - generic drugs make up
about 80% of total drug costs in America today , and these costs can
be just astronomical . What do yo u think the chances are that your
model could eventually expand in ways to the non - generic market ?

Mark Cuban: A 100% . One of the challenges that manufacturers of branded drugs
face is that they've been villainized . Using insulin as an example ,
e v erybody thin ks that they're responsible for the increasing cost to

Mark Cuban

patients for insulin, when we know , people in the industry know,
that's just not the case , that the price that manufacturers sell insulin
for has actually declined . And so part of why the y're excited to work
with Cost Plus Drugs , is the transparency. Now , patients and others in
the industry will be able to see exactly what we pay, and what we
charge.

Mark Masselli: We often hear that drug research and development is also baked into
the cos t to the consumer , and some say these low cost approaches
will dampen the pace of new drug development. What do you say?

Mark Cuban: Well, you have to ask who's saying that . It's the lobbyists that are
saying that . Manufacturers know that they're not going to b at 100%
on t heir drugs . And so there's a price associated with R&D , licensing
or purchasing, and then getting all the approvals and all the
marketing, there's a price associated with that , and so you've got to
build all that into how they price . Becau se the manufacture rs , for the
most part, don't actually have control of their own retail or net price
that's where a lot of distortions come in.

Part two, particularly as it applies to specialty drugs, which are the
ones that are very expensive, you know, there' s a differen t equation
for determining whether or not a price is fair . If there is a medication
that adds 10 years to your life and eliminates having to go to the
hospital , is $5 million too much ? You know, the cost of going through
care and being i n the h ospital to t ake care of that disease before the
medication was in place was greater than $5 million , we ll, somebody
saved money. The problem in all of this is that it's not the insurance
companies that are typically saving the money , and that create s the
pu sh - p ull that is creating problems as we talk about, especially
medications , and that creates a lot of what challenges for people
going to the specialty drug programs because the insurance
companies don't want to pay for them. They're trying to get the
manu facturers to provide these high - end expensive medications for
nothing so that the insurers don't have to pay what they're obligated
to pay.

But you've got this challenge that what the insurers want, and what
the patient wants, and what the manufac turer wa nts, are not aligned
at all. And so over the next five years, it's going to be very politically
expedient for some politicians to say, you know what, we need a
public - private partnership that excludes insurance companies so that
these high - end spec ialty dr ugs are eval uated to make sure that pricing
i s fair. One of the challenges for those specialty drug manufacturers is
percentage of valid patients receiving the medication , and them
getting paid for a medication , l et's just say for easy math , that h as a
million doll ar price tag, and has a potential annual patient base of
1 , 000 people . Right now, they're not going to be able to get approvals

Mark Cuban

for all 1 , 000 of those potential patients . It's more high - end , people
like me who are able to afford those thin gs .

And so through a public - private partnership, you'll be able to say to
them, “ Look, you can't charge a million dollars for these 1 , 000
patients. But we'll guarantee you that all 1 , 000 patients will be able to
pay for it , and you're only going to charge 500,000 so that you net out
at 500 million in revenue as opposed to your hope for $1 billion in
revenue. So that it's fair to you as a business . It's fair to the patients .
All of them , who have valid prescriptions from the provider , are able
to get it , wh ich is the most importa nt part , and we take the
organizations that are the inhibitors, the private insurers who don't
see the financial benefit from it . ” Their math probably says in their
models that they're not going to get a billion dollars in savings , s o
they do all they can to prevent paying for it . And so we need to be
honest and straightforward and have some transparency . And if the
manufacturers of the specialty drugs are willing to do that, and we're
able to everybody get on the same page, then I th ink we sav e a lot of
l ives and improve the health care system. If they don't, and we have
this continued push - pull where the insurers do their best to deny
claims or pre - authorizations, then we have problems.

Margaret Flinter: But let me pivot just a bit M ark , you know, the COVID p andemic
amplified so many shortcoming s, inadequacies in our health care
system , and supply chain was right at the top . But you're going to
actually be scaling up your own drug manufacturing factories for Cost
Plus Drugs . So tell u s about that . And what o the r supply chain issues
do you see as ri pe for disruption?

Mark Cuban: There are a lot of drugs that go into shortages where there's just not
enough of a market for a manufacturer to continuously produce
them , and so they just jack up the price. W e've seen th at happen
multiple times. You know, you have sterile water like now which is
hard to come by , and even though it's not hard to make, there's just
no manufacturers to do it. So , with Cost Plus Drugs , we're building ,
we're finishi ng out actually a manufacturi ng plant in Dallas, Texas that
is robotically driven so that it only takes us four hours to turn our
manufacturing from one injectable to the next.

Starting with things like sterile water, we'll talk to all the hospitals and
a ll the providers that need i t . We'll come up with a fair price that
covers our costs , because as a manufacturer, we can't just do it a
straight cost plus 15%, our costs are much higher, and we'll make it
available for whatever injectables are in short supp ly. And then it
t akes four ho urs for us to cycle to the next drug, we'll do the next one .
Then four hours, we'll do the next one , and so on and so forth. If it
works out well, we have plenty of room to expand for oral
medications . You name it , w e'll be abl e to expand to i t , presuming

Mark Cuban

that everything goes the way we expect it to.

Mark Masselli: Mark, I want to focus on one of the health companies you developed
Unite Genomics , which you say is focused in on advancing medicine
through large scale analysis of g enomic and healt h data. And I'm
wondering how will genomics and personalized medicine shift the
futur e of drug development landscape.

Mark Cuban: Well, the honest answer t o it, Mark , is I don't know . The guys at
genomics know their stuff and they run their show really, real ly well ,
but just generically, our bodies are one big math equation. We don't
know how many variables are in that equation. But every single day
with advancements and chips and GPUs and just about every other
core component of Artificial Intelligence , we'r e learning m ore and
more and more about our bodies. And when you start mixing those
together over time, you truly do get to the point where you have
more and more personalized medicine.

Margaret Flinter: But in health care, of course, the re's so much at sta ke , with fail ure in
any element of health care . What have your startup experiences in
other areas taught you about how you're going to go about this
process with your new company , doing it without harm?

Mark Cuban: Look, there's no mista ke - free anything anywhe re , whether i t's
healthcare, or selling nachos at a Mass game . The challenge for
patients , as it applies to health care , is we're not as transparent as we
need to be , and when you're not transparent, then people don't trust
it. You k now, if you think about the proc ess of getti ng a prescription,
you go to the doctor, and the doctor says, “ Sorry, you need to get
this . What's your pharmacy ? ” And then you just get the prescription
sent to your pharmacy . The pharmacy doesn't know what they 're
going to charge you until they ring it up. You're hoping all your
insurance covers it. I think the true missing piece, Margaret, is
transparency.

But I mean, look, look at just hospitals . They can't even get them to do
what's legally required o f them with transparent pricing on their
w ebsites. You know, I had a CT colonoscopy and I had a CT , just
because I do them every couple of years and I just pay cash price. I
don't even go through my insurance , simply because I kind of like
going through all the h ospital spreadsheet s to see wha t the pricing is.
Without transparency, there's not trust. And when you have
organizations creating reasons for them not to be trusted, then that's
where things go south and they become politicized. I mean, look , in
health ca re, what is it , 21% of the total c ost of health care in this
country is administrative , and there are so many easy things that you
can do. You can standardize contracts . Right ? Network contract for
every hospital use s standardized contract that is reviewed and cut the
cost and al l the resear ch that has to be done , i t has to go up the

Mark Cuban

flagpole six feet deep. And then the provider does everything possible
to complicate it. My mom died of cancer this past February .

Mark Masselli: Sorry to hear that.

Mark Cuban : And we went -- than k you. She w ent in to talk to the doctors , and the
doctor says she needed a PET scan. Okay, let's get her a PET scan
while she's here. No, you can't get a PET scan while you're in the
hospital. You have to come back more than three days later , so they
get paid the mos t . My mom was like, “ No . Do y ou know what it cost s?
It cost me and it cost my family . ” Because this is the ridiculousness
that patients have to face. And it's not like the hospitals don't know
what they're doing . When they u p - code , when they recod e , you
know, we saw all , the article in The New York Times for Medicare
Advantage . Right ? That's insane. Put me in charge. I'll make you
criminal if you do that , because once you create distrust in the health
care system, you get wha t we had with COVID whe re people do n't
trust.

You know, a friend of mine runs a hospital. Guys I grew up with run ,
there's several hospitals , and so I keep in touch with them . And they
had built this building and they were ask ing me what I thought was
the best approach , and I wa s like, “ Ther e's only one answer . Sell that
building, take that and reduce the rates, you know, and make it more
accessible. You don't need a fancy building. That's what you see on
every hospital campus. ” And you know what , I worked with a group
Toronto, Can ada . Their r eal estate is more expensive than Manhattan .
Their doctors get paid the same . Their nurses get paid the same as
hospitals in Manhattan. Why are all their procedures less than
Medicare ? And it's really simple when you s tart looking at it . They're
mostly non private rooms. I a ctually had kidney stones in Toronto one
time . They put me , just a little curtain around me. But it was not a
private room, and I was great. In our hospitals, it's all private rooms.

I n Canada, they pay for all the doct or s ’ liability insurance . The
hos pitals are sure they'll get paid for all the patients that come
through the door. These are little things that we complicate here in
the United States through no liability compensation. When you do
that , and there's not a lot of transparency, people aren' t going to
trust , and it's going to be more expensive, and people are going to go
without health care. And that's just insane.

Mark Masselli: Mark, on one side, you a re battling on the trust and transpar ency
side , and you're coming up against on the other s ide some legacy
players in the big pharma world with a lot of skin in the game . CVS
Caremark made about $150 billion in prescription drug space in 2021
alone . And Walmart and Costco have well establishe d supply chains
and market share . You've got Amazon t urning to direct consumer
drug purchasing as well . Use a basketball analogy, how do you

Mark Cuban

outshoot the legacy teams ? What's your edge in this really crowded
field , when so much profit is hanging in the bal ance?

Mark Cu ban: Well, there's this old sayin g I use all the time when you run with the
elephants there are the quick and the dead. We're really, really quick .
We're agile . We ’ re evolving all the time . We started off just mail
order . Hopefully within the next 60 to 90 days, w e'll have a discount
card , so you 'll be able to pick up at a local pharmacy at our pricing
because they'll buy from us and agree to our pricing. And on top of
that, rather than some of the other discount cards do , which is charge
the p harmac ies for the traffic , we’ll actuall y pay the pharmacies for
f ulfillment, which I think the pharmacies are going to love. So, that’s
one way to do it.

You know, Jeff Bezos ’ family said, “ Your margin is my opportunity . ”
And that's exactly what's goi ng on here. You know, Cost Plus D rugs
already has more than a million accounts . Nine months in , more than
a million accounts, and we're growing rapidly. By the time we finish
this, we might be at 1.1 million. And so if we get enough of a base,
people are goin g to want to keep on working with us no matter what
the other ones do. You know, maybe they come along and match our
pricing. Maybe they come along and do the same thing and just copy
us . If the net result is okay Cost Plus isn't as big as it might hav e
ot herwise been , b ut everybody's playing cost plus 15% , h ello, you
know, problem solved.

But , at the same time, when you're as big and public, to me, that’s the
big three. And there's so much right pocket , left pocket , where they
cre ate or buy this company w here the y send some margin there , a nd
then that company buys from another one of their subsidiaries and
they send some margin there. It's awful, awful hard for them to be
cost competitive. There's just too many layers and too much hierarchy
for that to wor k. I th ink we'll be okay. And I think our number one
product is not a medication, our number one product is trust. And if
those other outlets were truly trusted, we wouldn't have any
customers.

Mark Masselli: Mark, I heard you say i n the last answer to Mar garet's q uestion that if
someone puts you in charge, is this an announcement of any
candidacy that we can report on?

Mark Cuban: Oh, no, no, absolutely not . No, my family would disown me.
Absolutely not. But you know, some of these providers need skin in
t he game i n terms of their obligations to living up to the law. A $100
fine per day isn't going to make anybody change their actions. There's
just so many, you know, there's just so much money involved , a nd
that money keeps on gettin g bigger, and the fines become a smaller,
smaller percentage. You know, the minute somebody that works
anywhere in that food chain in a major corporation, ha s that fear of

Mark Cuban

going to jail , it all changes.

Margaret Flinter: Well Mark , I’ve read you're also pretty interested in the p otenti al for
new technologies like wearables and AI to improve health. In that
little bit of time you might have to think about those things right now ,
w hat's exciting you in AI and health sensors, digital health ? What else
out there captures your imaginat ion and your investor ’ s eye ?

Mark Cuban: All the above. I mean I'm a big believer that there's two types of
companies in this country, those who are great at AI , and everybody
else. If you look at the top 10 market share compan ies, they're great
at AI, you kno w, the Apples , the Googles, etc. And they're also great
at acquiring data. Now, we can argue about the privacy issues, but the
ability to use AI for personal health care is only going to improve.

You know, I got criticized for this like six - seven year s ag o when I
talked about it online, but I get my blood tested every four to six
months because I want my baseline to be my baseline , n ot Mark and I
be baseline d against the exact same numbers for what a male , white
male in our age group is supposed to be benchmarked at. And so I
started getting my own blood work . I go to capitalize that, connect it
with my eye Watch and capture that data. And the point being that
the more data we have availabl e to us, I think the smarter deci sions
we can make as patients . Y ou know, sometimes too much data is a
bad thing, because a lot of patients don't know what to do with it , a nd
they get caught up in a vortex or a rabbit hole trying to figure out
their own health care. But t hen again, that goes back to trust . If we're
able to trust our providers , if we're able to trust our doctors, and we
don't rush our doctors, and we give them a chance to explain what's
going on to the patients, and how this data actually impact s their
lives , then we start getting better outcomes.

And I t hink AI has a real role to play. And those are the things I look at .
I invested in a company Genetesis [inaudible 20:4 8] seven years ago I
think . What I didn't know when I invested in there ou t in Cincinnati, is
every one of the organs in our body emit an electrical signal , I had no
idea. And there are scanners that capture that electrical signal , a nd
the first one they work with is the heart. So they capture the elec trical
signal that comes out of t he heart. They save it as an audio file,
believe it or not , and then they r un it through machine learning AI.
And based off of tens of thousands of examples , t hey're able to
correlate what issues the patient might be having with their heart.
Because anybody our age knows that you feel something in your
chest, you immediately get nervous. And so many people go to the
hospital , and there is no quick way to resolve what that is. So you
might get checked in , you might get sent home. It's really, really
d ifficult . But using AI and Genetesis , they ’re going through their trials.
Now, t he hope is you get scanned, you run it through the AI , and it

Mark Cuban

tells you with some level of accuracy the most likely thing that's going
on with your heart. And so thing s like that to me have huge upside .
T hings that make us smarter, make us m ore efficient, allow us to do it
for less , t hose are all things that I think AI will drive , and that I get
excited about.

Mark Masselli: We've been s peaking with entrepreneur and Sha rk Tank host, Mark
Cuban, who has launched an online entity Cost Plus Drug s , seeking to
sh ake up the prescription drug market. You can follow our show and
learn more about all of our guests at www.chcradio.com . Mark, thank
you so much for joining us. And we'll continue to follow your
inno vations.

Mark Cu ban: Thank you. Thanks for having me on. And I encourage everybody , go
to www. cost plusdrugs.com , p ut in the name of your medication and
com pare it to what you're paying. If you're paying anything out - of -
pocket , w e're probably lower than your copay. And if you'r e an
organization, a company, whatever it may be , a clinic , do the same
thing , because we're probably cheaper than what your insurance
co mpany is charging you , and you can end up paying a lo t less in
premium. So , check us out. Thanks guys for having me on. It was a
great conversation. I really enjoyed it.

Mark Masselli: Take care.

Margaret Flinter: Thank you so much .

[ Music ]

Mark Masselli: At C onversations on Health Care we wa nt our audience to be truly in
the know when it comes to the facts about health care refor m and
policy. Lori Robertson is an award - winning journalist , and Managing
Editor of FactCheck.org, a nonpartisan, nonprofit consumer ad vocate for voters that aim to red uce the level of deception in U.S. Politics.
Lori, what have you got for us this week?

Lo ri Robertson: President Joe Biden signed into law the Inflation Reduction Act on
August 16. Part of the law deals with Medicare and pr escription drugs .
The law will lo wer at least s ome Medicare beneficiar y’s prescription
costs on Part D , that's Medicare's p rescription drug program , a nd on
Part B . The law requires the Federal government to negotiate prices
for some Medicare medications. It caps seniors ’ out - of - pocket drug
cost at $2,0 00 a year, it caps monthly insulin co pays at $35 , a nd it
limits Part D premi um increases. Again, that's all for Medicare, not
private health plans.

Republicans have focused on the price negotiation aspect , and t he
pharmaceutical industry has lo ng fought a gainst attempts to enact
such a policy. Their argument is that the policy woul d reduce the
number of new drugs pharmaceutical companies bring to market. The

Mark Cuban

nonpartisan Congressional Budget Office estimated there would be
just two fewer drugs la unched over the next decade under the
legislation. Seniors who spend more than $2,000 a y ear on
prescriptions , would clearly benefit . That cap on yearly spending
would launch in 2025 , a nd it could affect more than 1.4 million
beneficiaries based on 2020 enro llee data . Right now , out - of - pocket
costs of more than $7,050 for Part D drugs pushes seni ors into what's
called the catastrophic phase. They pay 5% of their drug costs after
that threshold. The Inflation Reduction Act elimi nates the 5% copay in
2024 , benef iting mo re than 1.3 million seniors. The cap on ins ulin
co pays also could affect millio ns. Seniors who now can't afford to buy
needed medicines also would benefit from the bill.

And that's my fact check for this week. I'm Lori Robertson, M anaging
Editor of FactCh eck.org.

[ Music ]

Margaret Flinter : FactCheck.org is committed to factual accuracy from the country's
major political players , and is a project of the Annenberg Public Policy
Center at the University of Pennsylvania. If you have a fact that you'd
lik e check ed, e - mail us at www.chcradio.com . We'll have
FactCheck.org's Lori Robertson check it out for you here on
Conversations on Health Care.

[ Music ]

Margaret Flinter : Each week , Conv ersations highlights a bright ide a abo ut how to make
wellness a part of our communities and everyday lives . An estimated
8 00 million people in the world lack access to electricity, and some 2
m illion people to clean water . And those living in Sub - Saharan A frica ,
a re most lacking in these e ssen tial resources. So called Ecopreneurs ,
Emiliano Cecchini and Davide Bonsignore , sough t to create a
sustainable solution for these communities that lacked not just these
vital resources, but the infrastructure needed to deliver them as well.
They engine ered a portable solution , the OffGridBox , a six foot by six
foot container that when ass embled on site with a solar panel roof ,
generates enough power to support a village ’ s basic energy needs.
And the box also contains a p ump and water purification system tha t
can provide more than 5000 gallons of clean filtered water per day. A
huge benefit for these communities who must carry containers of
often contaminated water over long distances from water sources
that are increasin gly diminished by climate change.

Emil iano Cecchini : So , these are subsistence economies, where people off the grid in
scar city of water are trying to produce and grow food. So , we go
there , and we provide safe drinking water , c lean p ower for basic
electricit y needs , power to pump water , and f or agriculture.

Mark Cuban

Margaret Flinter : The OffGridBox is managed by local operators who are tra ined on the
system's dedicated app, allowing villagers to update their energy use
and water production data every day. And locals are also trained as
technicians to t r oubleshoot problems that may arise. The goal is to
create a sustainable solution for comm unities most impacted by
climate change without adding to the global climate crisis .

Davide Bonsignore : Climate change, it's accelerati ng . The increase of price of fo ss il fuel is
accelerating. The problem is how we can develop technologies that
are usable a nd easily maintainable.

Mar garet Flinter : More than 70 OffGridBox systems have been installed across Sub -
Saharan Africa thus far, and c ommunity health has improved f rom
gaining consistent access to clean water. Farmers are able to expand
their crop yields , a nd economic opportunities evolve around the
sustainable source of clean water and renewable energy. The
OffGridBox , a sustainable renew able power source , providing energ y
for local schools, homes, clinics and entrepreneurs, as well as clean
potable water for drinking and farming, yielding increased health and
economic prosperity for communities that are struggling to survive in
some of the most climate challenged pa rts of the world , n ow that's a
bright idea.

[ Music ]

Mark Masselli: I'm Mark Masselli.

Margaret Flinter: And I'm Margaret Flinter.

Mark Masselli: Peace and Health.

[Music]

Marianne O’Hare : Conversations on Health Care is recorded in the Knowledge and
Techno logy C enter Studio s in Middletown , Connecticut, and is
brought to you by the Community Health Cen ter , now celebrating 50
years of providing quality care to the underserved , where health care
is a right not a privilege . ww w.chc1.com and www.chcradio.com .

[ Music ]